Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cancerlysin
- Development stage
- Preclinical
- Lead developer
- ImmuVia
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cancerlysin is a first-in-class bispecific apoptosis trigger (BAT) developed by ImmuVia. It utilizes a proprietary mechanism designed to efficiently cluster death receptors on the surface of cancer cells, thereby significantly enhancing the induction of apoptosis (programmed cell death). Unlike traditional therapies, BATs are engineered to target tumor cells specifically, minimizing damage to healthy tissues. The lead candidate, Cancerlysin IMV-M, has demonstrated broad anti-tumor efficacy in mouse xenograft models and a favorable safety profile in non-human primates. As of late 2024, the program remains in preclinical development.
- Other names
- Cancerlysin IMV-M
02
Targets
TNFRSF10B (DR5)MUC16 (Mucin-16)TNFR (TNF receptor family)
Beyond the preview
Go deeper on Cancerlysin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cancerlysin.